Charytan et al, AJKD, "Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)"

Table S7. Cause-specific cumulative incidence according baseline eGFR and treatment

Type of Death	Q1 0.9-24.2 mL/min/1.73m^2		Q2 24.3-31.6 mL/min/1.73m^2		Q3 31.7-40.2 mL/min/1.73m^2		Q4 40.3-119.8 mL/min/1.73m^2		P$_{trend}$ *	P$_{Interaction}$
	Placebo (N=540)	Darbepoetin (N=468)	Placebo (N=509)	Darbepoetin (N=505)	Placebo (N=476)	Darbepoetin (N=531)	Placebo (N=499)	Darbepoetin (N=507)		
Overall	32.9%	27.9%	17.9%	24.4%	19.9%	18.2%	17.3%	19.1%	<0.001	0.28
CV Death	15.9%	14.7%	11.2%	11.0%	12.3%	10.3%	9.4%	11.2%	<0.001	0.26
Fatal MI	2.6%	1.5%	3.0%	0.8%	0.9%	0.8%	1.2%	1.1%	0.07	0.52
Fatal Stroke	0.9%	1.8%	1.3%	1.6%	0.7%	1.3%	0.5%	0.7%	0.03	0.57
Presumed CV Death	1.8%	2.0%	1.0%	1.9%	1.8%	1.6%	0.2%	2.4%	0.23	0.06
Pump Failure	3.0%	1.7%	2.1%	1.3%	1.2%	1.4%	2.5%	1.9%	0.45	0.26
CV Other	0.8%	0.2%	1.1%	0.9%	1.1%	0.2%	0.8%	0.7%	0.62	0.69
Presumed Sudden Death	1.6%	1.1%	0.2%	1.1%	2.2%	0.9%	0.5%	0.4%	0.34	0.86
Definite Sudden Death	5.2%	6.3%	2.5%	3.3%	4.4%	4.1%	3.6%	4.0%	0.07	0.90
Definite or Presumed Sudden Death	6.8%	7.4%	2.7%	4.5%	6.6%	5.0%	4.1%	4.4%	0.04	0.97
Non-CV Death	14.1%	11.0%	5.4%	11.3%	6.5%	6.9%	6.2%	6.1%	<0.001	0.90
Infection	6.0%	3.7%	2.2%	3.1%	2.0%	2.0%	0.8%	2.3%	<0.001	0.09
Malignancy	1.8%	2.1%	1.0%	3.3%	1.3%	1.5%	1.6%	1.9%	0.43	0.57
Other	4.6%	3.3%	1.8%	3.5%	2.7%	2.2%	3.1%	1.5%	0.03	0.23
Renal	1.8%	1.9%	0.4%	1.4%	0.4%	1.2%	0.6%	0.4%	0.01	0.78
Unknown	2.8%	2.2%	1.1%	2.1%	1.1%	1.0%	1.7%	1.7%	0.17	0.69

* Adjusted for treatment. Cumulative incidence rates at 3-years. P values are for the interaction of treatment with eGFR. Renal deaths defined as refusal of dialysis, or death in the setting of acute kidney injury or from direct complications of uremia, dialysis, or renal procedure. Other deaths include suicide and deaths from pulmonary, hepatobiliary, gastrointestinal, procedural, and accidental causes.